Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 141Lymphoid 43Other hematologic neoplasm 35Thoracic 6Genitourinary 6Gastrointestinal 6Myeloid 4CNS 4Tumor-Agnostic 3Gynecologic 3Breast 3Head & Neck 2Dermatologic 2Other solid neoplasm 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 3surufatinib 2pembrolizumab 2olaparib 2lanreotide 2atezolizumab 2Everolimus 23-Iodobenzylguanidine 2tivozanib 1tislelizumab 1repotrectinib 1regorafenib 1pralsetinib 1irinotecan sucrosofate 1cabozantinib 1avelumab 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1Tirapazamine 1Temozolomide 1TKM-080301 1S 1 (combination) 1Radiotherapy 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1PT-100 dipeptide 1PM 01183 1Ondansetron 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Dexamethasone × NET × Clear all
NCT02592707 2023-07-19

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Ipsen

Phase 1/2 Terminated
40 enrolled 37 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡